The screenshots below are examples of buyers of domains from the past few months that have either developed their sites, or purchased an upgrade domain and have redirected their acquisition to an existing website.
Snowflake.co.uk sold for $15,500 at Sedo, and it was an additional domain for the California-based company that resides on Snowflake.net. “Snowflake is the only data warehouse built for the cloud, and now your cloud data warehouse = your cloud”.
Oberlo.ca sold for $15,000 at Flippa, and the owner is Baremetal.Com Inc. They have a similar site live on the .com, but they don’t appear to own that domain. “Oberlo allows you to easily import dropshipped products directly into your ecommerce store and ship them directly to your customers – in only a few clicks.”
UJW.com sold for $14,300 at NameJet, and a Chinese language site is live as shown below. I can’t tell for certain if it’s just a placeholder or a ‘real’ site, but it sure appears real. Per Google Translate, an education-related site is live, “Eugenics for novice parents to provide the best quality of education information, early childhood education, family education and other information and knowledge, but also for kindergarten teachers and other early childhood education practitioners to provide teaching cases!“
Baze.com sold for $14,000 at Sedo, and a vitamin related site is getting ready to launch. “Only Baze measures your actual vitamin levels and provides you with the highest-quality vitamins tailored to your body’s needs. With personalized daily vitamins, Baze brings your body into its optimum state.”
SitePad.com sold for $13,000 at Sedo, and a website builder is live, from the folks behind Softaculous.com. “Our Mission is, “To help users choose the best web softwares through ratings, reviews and user experiences given by users around the world and installing web softwares with great ease.””
Miragen.com sold for $4,000 at Sedo, and the domain is an upgrade from MiragenRX.com. The Boulder, Colorado-based company describes itself as, “a clinical stage biopharmaceutical company developing innovative microRNA-targeting therapies to improve human health.”
